Figure 3 | Scientific Reports

Figure 3

From: Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease

Figure 3

Distribution of V565 and V900 in the faeces of mice following oral administration. Four naïve mice were each administered a mixture of 146 µg V900 and 140 µg V565. Faeces were collected between 0–3 and 3–6 h and V565 and V900 levels in faecal extracts were measured by biotinylated adalimumab competition ELISA and IL-23/IL-23R ELISA, respectively. Concentrations shown are those calculated in the undiluted faeces. Error bars =  +/− SD.

Back to article page